About

Seagen and Astellas previously entered a clinical collaboration agreement with MSD to evaluate the combination of Seagen's and Astellas' PADCEV TM (enfortumab vedotin) and MSD's KEYTRUDA ® (pembrolizumab) in patients with urothelial cancer. Pfizer Inc. successfully completed its acquisition of Seagen on December 14, 2023. KEYTRUDA is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Rahway, NJ, USA (known as MSD outside of the United States and Canada). About XTANDI and the Pfizer/Astellas Collaboration In October 2009, Medivation, Inc., which is now part of Pfizer, and Astellas (TSE: 4503) entered into a commercial agreement to jointly develop and commercialize XTANDI ® (enzalutamide) in the United States, while Astellas has responsibility for manufacturing and all additional regulatory filings globally, as well as commercializing the product outside the United States.